## Atazanavir: Optimal PI Profile **Key Point:** Atazanavir (ATV/r) offers the lowest pill burden among boosted PIs and superior GI tolerability, making it a preferred choice in resource-limited and developed settings. ### Pharmacokinetic Advantages | Feature | Atazanavir | Lopinavir | Darunavir | Indinavir | |---------|-----------|----------|----------|----------| | **Pill burden** | 2 caps/day | 4 tabs/day | 2 tabs/day | 3 caps/day | | **Food requirement** | Yes (↑ absorption) | Yes | Yes | Yes (fasting preferred) | | **GI tolerability** | Excellent | Poor (diarrhea) | Good | Moderate | | **Renal toxicity** | None | None | None | Nephrolithiasis (10%) | | **Hyperbilirubinemia** | Yes (benign) | No | No | No | **High-Yield:** Atazanavir's unconjugated hyperbilirubinemia is **benign and reversible** — it does NOT indicate hepatotoxicity and does not require discontinuation. ### Clinical Advantages of Atazanavir/r 1. **Low pill burden:** 2 capsules once daily (with ritonavir booster) 2. **Excellent GI tolerability:** Minimal diarrhea compared to lopinavir 3. **Cardiovascular safety:** No adverse lipid profile 4. **Integrase inhibitor compatibility:** Can be used with DTG, BIC, EVG 5. **Pregnancy-safe:** Suitable for women of childbearing age **Mnemonic:** **ATV = A Terrific Viable** option (low pill burden, tolerable) ### Why Other PIs Are Suboptimal - **Lopinavir/r:** High pill burden (4 tablets) and frequent diarrhea limit adherence - **Darunavir/r:** Requires 2 tablets but less widely available in resource-limited settings - **Indinavir/r:** Nephrolithiasis risk (10%), requires high fluid intake, and GI side effects **Clinical Pearl:** Atazanavir must be taken with food and separated from antacids/H~2~ blockers by ≥2 hours to ensure adequate absorption.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.